IKNA - Ikena Oncology, Inc. Stock Price, Fair Value and News

$6.70-0.20 (-2.90%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IKNA Price Action

Last 7 days

-2.9%

Last 30 days

-21.5%

Last 90 days

-50.0%

Trailing 12 Months

-66.0%

IKNA RSI Chart

IKNA Valuation

Market Cap

74.9M

Price/Earnings (Trailing)

-2.11

Price/Sales (Trailing)

12.91

EV/EBITDA

0.27

Price/Free Cashflow

-3.38

IKNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IKNA Fundamentals

IKNA Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

IKNA Earnings

Earnings (TTM)

-35.6M

Earnings Growth (Yr)

-142.33%

Earnings Growth (Qtr)

-226.96%

IKNA Profitability

EBT Margin

-607.00%

Return on Equity

-25.44%

Return on Assets

-22.11%

Free Cashflow Yield

-29.6%

IKNA Investor Care

Shares Dilution (1Y)

47074.00%

Diluted EPS (TTM)

-21.09

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	7.0M	0	0	0
2024	6.5M	0	5.0M	3.5M
2023	17.5M	19.2M	14.0M	8.0M
2022	30.9M	27.7M	30.4M	15.6M
2021	9.4M	9.9M	10.8M	31.0M
2020	0	0	0	9.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Ikena Oncology, Inc.

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

CEO	Dr. Mark Manfredi Ph.D.
WEBSITE	https://ikenaoncology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	59

Ikena Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Ikena Oncology, Inc.? What does IKNA stand for in stocks?

IKNA is the stock ticker symbol of Ikena Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ikena Oncology, Inc. (IKNA)?

As of Mon Dec 01 2025, market cap of Ikena Oncology, Inc. is 74.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IKNA stock?

You can check IKNA's fair value in chart for subscribers.

Is Ikena Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether IKNA is over valued or under valued. Whether Ikena Oncology, Inc. is cheap or expensive depends on the assumptions which impact Ikena Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IKNA.

What is Ikena Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 01 2025, IKNA's PE ratio (Price to Earnings) is -2.11 and Price to Sales (PS) ratio is 12.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKNA PE ratio will change depending on the future growth rate expectations of investors.